CCWM
SRPT icon

Cassaday & Co Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Cassaday & Co Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54 Hold
3
– – ﹤0.01% 1297
2026
Q1 		$66 Buy
+3
New +$58 ﹤0.01% 1342

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cassaday & Co Wealth Management's SRPT Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 3 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

Cassaday & Co Wealth Management first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $66 in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Cassaday & Co Wealth Management held 3 shares of Sarepta Therapeutics worth $54 as of Q2 2026.
  • Cassaday & Co Wealth Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1297 holding.
  • Cassaday & Co Wealth Management first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Cassaday & Co Wealth Management's Sarepta Therapeutics position peaked at $66 in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.